Regeneron Pharmaceuticals Inc. buy Subdi
Summary
This prediction ended on 08.02.17 with a price of €318.51. The prediction for Regeneron Pharmaceuticals Inc. disappointed with a performance of -18.14%. Subdi has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -1.959% | -1.959% | 24.857% | -13.636% |
| iShares Core DAX® | 0.231% | -2.413% | 15.337% | 45.097% |
| iShares Nasdaq 100 | 1.663% | -1.658% | 31.087% | 76.365% |
| iShares Nikkei 225® | -0.208% | -2.502% | 43.625% | 49.585% |
| iShares S&P 500 | 1.067% | -1.579% | 24.346% | 57.069% |
Comments by Subdi for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Subdi stimmt der Buy-Einschätzung von piccolo90 zu
Biotech sollte nach dem Einbruch jetzt wieder gut laufen. Regeneron ist eine Gewinnmaschine mit guten Zukunftsaussichten.
http://www.godmode-trader.de/analyse/regeneron-setzt-zum-grossen-sprung-an,4808178
Subdi stimmt am 02.08.2016 der Buy-Einschätzung von piccolo90 mit dem Kursziel 525,24$ zu.
Überschrift: piccolo90 stimmt dem Sentiment von 'Buy' zu